Soricimed Biopharma Inc
Recherche - Sackville

2006Soricimed Biopharma Inc.Soricimed Biopharma Inc. is dedicated to advancing the development and commercialization of its therapeutic and diagnostic programs. Using focused innovative strategies in collaboration with major worldclass cancer research institutions, Soricimed's drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce tumour growth and volume with no demonstrable toxicity. Soricidin is the basis for Soricimed's targeted cancer management program focused on advanced solid tumours of epithelial origin. Soricimed is a clinicalstage private drug and diagnostic development company created in 2005 following the discovery and development of a proprietary peptide, soricidin. Soricimed is in the midst of a Phase I multicenter, openlabel, dose escalation study, taking place at cancer centres in both Canada and the United States.TechnologyThe technologies that Soricimed is developing arise from the abilities of our peptides to modulate ion channel activity.